ACAD NDA lowers the risk dramatically. Good luck with both. Keep in touch.
Hey these guys should take a look at AVXL-Alzheimers Dis treatment for cognitive decline and disease modifying. Had a major day today. Its small molecule, great side effect profile, excellent efficacy. ACAD/PDP, AVXL/AD and ITCI/SCHIZOPHRENIA. All similar, save one thing. AVXL is $1.36. Imagine buying ACAD when it was $1.36 Thats the way I see it.
Sophisticated...please. Ever see how they short, its minute to minute...short here ...cover there and make $250 and they feel like Gods Gift. They love to brag about their earnings, name call every stock, post unsubstantiated garbage. They have so many alias they could start their own phone book.
Exactly. We might see a little profit taking, but I think now the strength of this stock is starting to shine.
Because AD is not "rare". Now I am not sure if A2-73 would qualify due to "condition upon request of a sponsor ". I believe even if granted its more of a monetary advantage for rare drug developers, ie, "Priority Review" will be a no brainer for A2-73 anyway. """Designating an Orphan Product: The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphan status”). For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDA’s implementing regulations at 21 CFR Part 316. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated. A sponsor seeking orphan designation for a drug must submit a request for designation to OOPD with the information required in 21 CFR 316.20 and 316.21. Each designation request must stand on its own merit. Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated product must submit their own data and information in support of their designation request. The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies.""" fda.gov/
Incredible comeback on 1) Better than average Volume. 2) No news 3) IBB Down 4) There was major odds the shorts were going all out for AVXL today -Seeking alpha article today. 5) Pre-Market price drop 6) Bounced off ~ $1 as predicted by a few longs here. 7) Shorts got Corn Rolled.
Most stood their ground and didn't panic which is what the shorts count on. Congrats fellow longs.
Getting close to IGNORING you and your chart friend.
wanshun @wanshun_ 2h2 hours ago
$AVXL I was short a bunch o/n and added on morning wash. Tried to cover on dips on the grind back up.
$AVXL I was dead wrong on this today, basically flat on it now.
$AVXL proving to be more resilient than I expected as usual, still a nice trade but gave back a bunch
WHEN SHORTS SAY THEY ARE "FLAT"...THEY MEAN THEY LOST A TON.